Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Executive Summary

Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.

You may also be interested in...

Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?

FDA panelists' confusion over biosimilarity and overwhelming approval endorsements following glowing agency reviews suggest the meetings may not be having much impact on FDA deliberations; however, agency sees an opportunity to learn from what its external experts don't understand about biosimilars.

Edging Toward Interchangeability in Biosimilars

An impressive performance by Sandoz at the July 13 Arthritis Advisory Committee on its etanercept biosimilar application suggests progress on the learning curve towards interchangeable applications.

Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability

Study and formulation requirements under PREA mean that interchangeability application might not be much more of a leap.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts